Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 17

1.

18F-DCFPyL PET/CT Imaging in Patients with Biochemical Recurrence Prostate Cancer after Primary Local Therapy.

Mena E, Lindenberg ML, Turkbey IB, Shih JH, Harmon SA, Lim I, Lin FI, Adler S, Eclarinal P, McKinney Y, Citrin D, Dahut W, Wood B, Krishnasamy V, Chang R, Levy E, Merino M, Pinto P, Eary JF, Choyke PL.

J Nucl Med. 2019 Nov 1. pii: jnumed.119.234799. doi: 10.2967/jnumed.119.234799. [Epub ahead of print]

PMID:
31676732
2.

Imaging of subclinical haemopoiesis after stem-cell transplantation in patients with haematological malignancies: a prospective pilot study.

Williams KM, Holter-Chakrabarty J, Lindenberg L, Duong Q, Vesely SK, Nguyen CT, Havlicek JP, Kurdziel K, Gea-Banacloche J, Lin FI, Avila DN, Selby G, Kanakry CG, Li S, Scordino T, Adler S, Bollard CM, Choyke P, Gress RE.

Lancet Haematol. 2018 Jan;5(1):e44-e52. doi: 10.1016/S2352-3026(17)30215-6. Epub 2017 Dec 14.

3.

Superiority of 68Ga-DOTATATE over 18F-FDG and anatomic imaging in the detection of succinate dehydrogenase mutation (SDHx )-related pheochromocytoma and paraganglioma in the pediatric population.

Jha A, Ling A, Millo C, Gupta G, Viana B, Lin FI, Herscovitch P, Adams KT, Taïeb D, Metwalli AR, Linehan WM, Brofferio A, Stratakis CA, Kebebew E, Lodish M, Civelek AC, Pacak K.

Eur J Nucl Med Mol Imaging. 2018 May;45(5):787-797. doi: 10.1007/s00259-017-3896-9. Epub 2017 Dec 4.

4.

Beyond Correlations, Sensitivities, and Specificities: A Roadmap for Demonstrating Utility of Advanced Imaging in Oncology Treatment and Clinical Trial Design.

Huang EP, Lin FI, Shankar LK.

Acad Radiol. 2017 Aug;24(8):1036-1049. doi: 10.1016/j.acra.2017.03.002. Epub 2017 Apr 26. Review.

5.

Beyond Correlations, Sensitivities, and Specificities: Case Examples of the Evaluation of Advanced Imaging in Oncology Clinical Trials and Cancer Treatment.

Lin FI, Huang EP, Shankar LK.

Acad Radiol. 2017 Aug;24(8):1027-1035. doi: 10.1016/j.acra.2016.11.024. Epub 2017 Apr 11. Review.

6.

Functional Imaging Signature of Patients Presenting with Polycythemia/Paraganglioma Syndromes.

Janssen I, Chen CC, Zhuang Z, Millo CM, Wolf KI, Ling A, Lin FI, Adams KT, Herscovitch P, Feelders RA, Fojo AT, Taieb D, Kebebew E, Pacak K.

J Nucl Med. 2017 Aug;58(8):1236-1242. doi: 10.2967/jnumed.116.187690. Epub 2017 Mar 23.

7.

Utility of 18F-fluoroestradiol (18F-FES) PET/CT imaging as a pharmacodynamic marker in patients with refractory estrogen receptor-positive solid tumors receiving Z-endoxifen therapy.

Lin FI, Gonzalez EM, Kummar S, Do K, Shih J, Adler S, Kurdziel KA, Ton A, Turkbey B, Jacobs PM, Bhattacharyya S, Chen AP, Collins JM, Doroshow JH, Choyke PL, Lindenberg ML.

Eur J Nucl Med Mol Imaging. 2017 Mar;44(3):500-508. doi: 10.1007/s00259-016-3561-8. Epub 2016 Nov 21.

PMID:
27872957
8.

Brown Adipose Reporting Criteria in Imaging STudies (BARCIST 1.0): Recommendations for Standardized FDG-PET/CT Experiments in Humans.

Chen KY, Cypess AM, Laughlin MR, Haft CR, Hu HH, Bredella MA, Enerbäck S, Kinahan PE, Lichtenbelt Wv, Lin FI, Sunderland JJ, Virtanen KA, Wahl RL.

Cell Metab. 2016 Aug 9;24(2):210-22. doi: 10.1016/j.cmet.2016.07.014. Review.

9.

PET/CT comparing (68)Ga-DOTATATE and other radiopharmaceuticals and in comparison with CT/MRI for the localization of sporadic metastatic pheochromocytoma and paraganglioma.

Janssen I, Chen CC, Millo CM, Ling A, Taieb D, Lin FI, Adams KT, Wolf KI, Herscovitch P, Fojo AT, Buchmann I, Kebebew E, Pacak K.

Eur J Nucl Med Mol Imaging. 2016 Sep;43(10):1784-91. doi: 10.1007/s00259-016-3357-x. Epub 2016 Mar 21.

PMID:
26996779
10.

PET/CT imaging of renal cell carcinoma with (18)F-VM4-037: a phase II pilot study.

Turkbey B, Lindenberg ML, Adler S, Kurdziel KA, McKinney YL, Weaver J, Vocke CD, Anver M, Bratslavsky G, Eclarinal P, Kwarteng G, Lin FI, Yaqub-Ogun N, Merino MJ, Linehan WM, Choyke PL, Metwalli AR.

Abdom Radiol (NY). 2016 Jan;41(1):109-18. doi: 10.1007/s00261-015-0599-1.

PMID:
26830617
11.

Preclinical efficacy of the anti-hepatocyte growth factor antibody ficlatuzumab in a mouse brain orthotopic glioma model evaluated by bioluminescence, PET, and MRI.

Mittra ES, Fan-Minogue H, Lin FI, Karamchandani J, Sriram V, Han M, Gambhir SS.

Clin Cancer Res. 2013 Oct 15;19(20):5711-21. doi: 10.1158/1078-0432.CCR-12-1015. Epub 2013 Aug 27.

12.

Prospective comparison of combined 18F-FDG and 18F-NaF PET/CT vs. 18F-FDG PET/CT imaging for detection of malignancy.

Lin FI, Rao JE, Mittra ES, Nallapareddy K, Chengapa A, Dick DW, Gambhir SS, Iagaru A.

Eur J Nucl Med Mol Imaging. 2012 Feb;39(2):262-70. doi: 10.1007/s00259-011-1971-1. Epub 2011 Nov 8.

PMID:
22065013
13.

Radiotracer visualization within a saline breast implant due to inadvertent needle penetration during lymphoscintigraphy.

Lin FI, Foster CC, Shelton DK.

Clin Nucl Med. 2011 Nov;36(11):1023-4. doi: 10.1097/RLU.0b013e318219b12a. No abstract available.

PMID:
21975393
14.

The fate and toxicity of Raman-active silica-gold nanoparticles in mice.

Thakor AS, Luong R, Paulmurugan R, Lin FI, Kempen P, Zavaleta C, Chu P, Massoud TF, Sinclair R, Gambhir SS.

Sci Transl Med. 2011 Apr 20;3(79):79ra33. doi: 10.1126/scitranslmed.3001963.

15.

Current concepts and future directions in radioimmunotherapy.

Lin FI, Iagaru A.

Curr Drug Discov Technol. 2010 Dec;7(4):253-62. Review.

PMID:
21034409
16.

Extensive FDG uptake in accessory muscles of respiration in a patient with shortness of breath.

Lin FI, Foster CC, Hagge RJ, Shelton DK.

Clin Nucl Med. 2009 Jul;34(7):428-30. doi: 10.1097/RLU.0b013e3181a7d1a9. No abstract available.

PMID:
19542946
17.

Merlin differs from moesin in binding to F-actin and in its intra- and intermolecular interactions.

Huang L, Ichimaru E, Pestonjamasp K, Cui X, Nakamura H, Lo GY, Lin FI, Luna EJ, Furthmayr H.

Biochem Biophys Res Commun. 1998 Jul 30;248(3):548-53.

PMID:
9703963

Supplemental Content

Support Center